Peter Foley (P Foley)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Venues

The Australasian journal of dermatology

The Journal of dermatological treatment

Dermatology and therapy

The British journal of dermatology

St Vincent's Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

St Vincent's Hospital

Australia

Head of Dermatology Research :: Dermatology

Probity Medical Research

Canada

Associate Investigator

Skin and Cancer Foundation

Australia

Director of Research

The University of Melbourne

Australia

Associate Professor :: Medicine

Publications

Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Patrick D Mahar, Susan J Robertson, David Orchard, Christopher Baker, Peter Foley
Paediatric indications and dosing guidance for advanced targeted treatments in Australia. The Australasian journal of dermatology 65 (4) (2024)
Zachary Holmes, Michelle S Goh, Peter Foley, Benjamin S Daniel
Tildrakizumab use for recalcitrant pityriasis rubra pilaris. The Australasian journal of dermatology 65 (5) (2024)
Zachary Holmes, Michelle S Goh, Peter Foley, Benjamin S Daniel
Tildrakizumab use for recalcitrant pityriasis rubra pilaris. The Australasian journal of dermatology (2024)
Patrick David Mahar, Anna Crothers, Peter Foley, Joseph Thomas
Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem? The Australasian journal of dermatology (2024)
Patrick D Mahar, Susan J Robertson, David Orchard, Christopher Baker, Peter Foley
Paediatric indications and dosing guidance for advanced targeted treatments in Australia. The Australasian journal of dermatology (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Peter Foley, Patrick D Mahar, Saxon D Smith, Monisha Gupta, Nicholas Manuelpillai, David Orchard, Li-Chuen Wong, John C Su, Amelia C James, Gayle Fischer, Gillian Marshman, Morton Rawlin, Murray Turner, Emma King, Robyn Kennedy, Christopher Baker
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patients. The Australasian journal of dermatology (2024)
Peter Foley, Kurt Gebauer, John R Sullivan, Erin K McMeniman, Stephen Shumack, Jonathan Ng, Amelia C James, Morton Rawlin, Shireen Sidhu, Dev Tillakaratne, Murray Turner, Barbara Radulski, Peter Nash, Christopher Baker
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients. The Australasian journal of dermatology (2023)
Joseph Frank Merola, Albert S Chiou, Emmanuel H During, Antonio Costanzo, Peter Foley, Amani Alfalasi, Shaila Gogate, Andreas Pinter, Roni P Dodiuk-Gad, Dagmar Simon, Marie Tauber, Richard B Weller, José Juan Pereyra-Rodriguez, Marius Ardeleanu, Jiangming Wu, Zafer E Ozturk
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study. The British journal of dermatology (2023)
Peter Foley, Nicholas Manuelpillai, Con Dolianitis, Geoffrey D Cains, Eric Mate, Rebecca Tronnberg, Christopher Baker
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study). The Australasian journal of dermatology 63 (3) (2022)
Peter Foley, Yves A Kerdraon, John P Hogden, Stephen Shumack, Lynda Spelman, Deshan Frank Sebaratnam, Charles S Su, Constance H Katelaris
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. The Australasian journal of dermatology 63 (4) (2022)
Sarah Ringin, Christopher S Baker, Peter Foley, Benjamin S Daniel
Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital. Dermatologic therapy 34 (6) (2021)
Kristian Reich, Kenneth B Gordon, Bruce E Strober, April W Armstrong, Megan Miller, Y K Shen, Y You, C Han, Y W Yang, Peter Foley, Christopher Ernest Maitland Griffiths
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. The British journal of dermatology (2021)
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Megan Miller, Y K Shen, Yin You, Chenglong Han, Kenneth B Gordon
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American journal of clinical dermatology 21 (6) (2021)
Christopher Ernest Maitland Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, Maria-Concetta Fargnoli, Delphine Staumont-Sallé, H Chih-Ho Hong, Jose Sánchez-Carazo, Peter Foley, Seong Jun Seo, Jérôme Msihid, Zhen Chen, Sonya L Cyr, Ana Beatris Rossi
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatology and therapy 11 (4) (2021)
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn C Guenther, Melinda J Gooderham, Laura K Ferris, Christopher E M Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim A Papp
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and therapy 10 (3) (2020)
Kristian Reich, Peter Foley, Chenglong Han, Sean McElligott, Erik Muser, Nan Li, April W Armstrong
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. The Journal of dermatological treatment 31 (6) (2019)

Peter Foley.css-eqlu8i{font-size:small;padding-left:4px;} (P Foley)

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Foley (P Foley)